PTO/SB/08a (08-03) Approved for use through 07/31/2006. OMB 0651-0031

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known			
		•		Application Number	10/532,067		
INFORMATION DISCLOSURE				Filing Date	December 28, 2005		
STATEMENT BY APPLICANT			NT	First Named Inventor	SUTTER, GERD		
		Art Unit	1648				
(use as many sheets as necessary)				Examiner Name	Hurt, Sharon L.		
Sheet	1	of	2	Attorney Docket Number	GRUE-004		

	C:1-	I Been and Marches	U.S. PATENT I	Name of Patentee or	Pages, Columns, Lines, Where
Examiner Initials'	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant
111110015	INU.	Number-Kind Code ² (if known)	MIM-DD-TTTT	Applicant of Cited Document	Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			
······································		US-			
		US-	<u> </u>		

FOREIGN PATENT DOCUMENTS							
Examiner Initials'	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁶ (# known)	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶	

Examiner Signature	871	Date · Considered	12-28-06	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

				Complete if Known		
Substitute	Substitute for form 1449B/PTO			Application Number	10/532,067	
INFORMATION DISCLOSURE				Filing Date	December 28, 2005	
STATEMENT BY APPLICANT				First Named Inventor	SUTTER, GERD	
				Art Unit	1648	
	(use as many sheets as ne	cessai	y)	Examiner Name	Hurt, Sharon L.	
Sheet	2	of	2	Attorney Docket Number	GRUE-004	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
Sh		BLANCHARD et al., "Modified Vaccinia Virus Ankara Undergoes Limited Replication in Human Cells and Lacks Several Immunomodulatory Proteins: Implications for Use as a Human Vaccine", (1998), Journal of General Virology, Vol. 79, pp. 1159-1167.	
8r		SCHEIFLINGER et al., "Evaluation of the Thymidine Kinase (TK) Locus as an insertion site in the highly attenuated vaccinia MVA Strain", (1996), Archives of Virology, Vol. 141, pp. 663-669.	
Examiner Signature		Sharin Date Considered Dec 28, 20	ರಿ ८

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.